Issues
-
Cover Image
Cover Image
To assess the effect of ionizing radiation combined with a MMP inhibitor on tumor angiogenesis, we prospectively and dynamically evaluated neovessels with Doppler ultrasonography on s.c. melanomas in four treatment groups: (a) Control group (no irradiation, sterile PBS injections; top panel); (b) Radiation alone group (locally irradiated at a dose of 2x12.5 Gy; bottom left panel); (c) Drug alone group (continuous treatment with Metastat 5 days at 2.5 µg/kg/d; middle panel); and (d) Combined treatment group (concomitant ionizing radiation plus Metastat scheduling: Metastat 5 days at 2.5 µg/kg/d started 24 hours before 2x12.5 Gy ionizing radiation; bottom right panel). In these experiments, ionizing radiation antiangiogenic effects were enhanced by the simultaneous administration of Metastat; this observation correlates well with the tumor growth inhibition. Combining a MMP inhibitor with ionizing radiation in this model provided in vivo evidence of antitumor efficacy through targeting of ionizing radiation-induced invasion and angiogenesis and suggests the possible use of Metastat with radiation therapy in early clinical trials. For details, see Kaliski et al.in this issue.
- PDF Icon PDF LinkTable of Contents
Minireview
ARTICLE
Biological and molecular properties of a new αvβ3/αvβ5 integrin antagonist
A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells
Determination of the importance of the stereochemistry of psorospermin in topoisomerase II–induced alkylation of DNA and in vitro and in vivo biological activity
A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy
Meeting Report
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.